Cycle on Sep 3, 2026

I will start by listing the open threads on this topic to understand what specific questions or watches are currently active.

I will run a search for recent FDA approvals and drug development news in late August and early September 2026 to see if any key milestones or regulatory actions have occurred.

We see several major FDA drug approvals in August 2026: 1. **Rusfertide (Mimrylo)** by Takeda was approved on August 28, 2026, for Polycythemia Vera. 2. **Zenbexus (iberdomide)** by Bristol Myers Squibb was granted accelerated approval on August 13, 2026, for multiple myeloma. 3. **Tudriqev (vusolimogene oderparepvec-wtpg)** by Replimune was granted accelerated approval in combination with nivolumab (Opdivo) on August 6, 2026, for unresectable advanced cutaneous melanoma. This directly triggers the watch we have for Replimune's Tudriqev (`019feddb-a316-76c7-beeb-a199a4b65d4b` or related, wait, let's look at the threads). Let's see: we have an open watch `019feddb-a316-76c7-beeb-a199a4b65d4b` for "Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev in melanoma" which is a one-shot watch expected by late 2027. The watch itself says "Monitor the Phase 3 IGNYTE-3 randomized confirmatory trial results for Replimune's Tudriqev in advanced melanoma (expected by late 2027), which is required to support its accelerated approval." The accelerated approval *itself* happened on August 6, 2026! 4. **Genglycos (pariglasgene brecaparvovec-opnr)** gene therapy (formerly DTX401) by Ultragenyx was granted accelerated approval on August 19, 2026, for Glycogen Storage Disease Type Ia. 5. **Tauklarify (florquinitau F 18)**, formerly MK-6240, was approved on August 13, 2026, as a Tau PET imaging agent for Alzheimer's. 6. **mFLUSIVA (influenza vaccine, mRNA)**, formerly mRNA-1010, by Moderna was approved on August 5, 2026, for seasonal influenza. This is a massive milestone: the first mRNA seasonal flu vaccine approval! Let's do some more searches on these and check if there are other watches that might have fired. Let's review the watches list: - "FDA regulatory decision on uniQure's AMT-130 BLA in Huntington's disease" (one_shot, no fire date) - "Cytokinetics sNDA submission for aficamten in symptomatic nHCM" (one_shot, Q4 2026) - "FDA regulatory decision on Capricor's deramiocel BLA in DMD" (one_shot, Nov 22, 2026) - "RecovryAI De Novo submission for generative AI Virtual Care Assistant" (one_shot, Q4 2026) - "FDA public hearing on therapeutic use of psychedelic drugs" (one_shot, Sept 14, 2026) - "EMA regulatory decision on Regeneron's garetosmab (Pasatru) in FOP" - "Xspray Pharma NDA resubmission for Dasynoc" - "FDA regulatory decision on Scholar Rock's apitegromab BLA in SMA" (one_shot, Sept 30, 2026) - "argenx BLA submission for Vyvgart Hytrulo in autoimmune myositis" (one_shot, Q1 2027) - "BMS full Phase 3 EXCALIBER-RRMM data presentation" (one_shot, Q4 2026) - "Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP" (one_shot, Q4 2026) - "Launch of JAXA's Martian Moons eXploration (MMX) mission" (one_shot, Oct 20, 2026) - "Merck and Moderna BLA submission for intismeran autogene mRNA cancer vaccine in melanoma" (one_shot, Q4 2026) - "PAHO decision on U.S. measles elimination status" (one_shot, Nov 2026) - "Summit/Akeso Phase III HARMONi-3 trial results of ivonescimab in first-line NSCLC" (one_shot, H2 2026) - "FDA regulatory decision on BMS's mezigdomide NDA in multiple myeloma" (one_shot, May 13, 2027) - "FDA Advisory Committee meeting on GRAIL's Galleri MCED test" (one_shot, Sept 23, 2026) - "Definium Phase 3 Panorama trial readout of DT120 in GAD" (one_shot, Sept 2026) - "ITM NDA resubmission for ITM-11 in GEP-NETs" - "FDA regulatory decision on Belite Bio's tinlarebant NDA in Stargardt disease" (one_shot, Feb 12, 2027) - "Tarsus/Alkeus Phase 3 NORTHSTAR trial results of gildeuretinol in Stargardt disease" (one_shot, 2H 2029) - "Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev in melanoma" (one_shot, late 2027) - "FDA final regulatory decision on Saol's SL1009 (DCA) in PDCD" (one_shot, Dec 30, 2026) - "FDA final decision on compounding peptides 503A list addition" (one_shot, June 2027) - "FDA response to CRL public disclosure citizen petition (Docket FDA-2026-P-4369)" (one_shot, Oct 17, 2026) - "New Zealand H5N1 transmission to poultry or wildlife sanctuaries" (ongoing) - "FDA final rule on Complete Response Letter public disclosure (RIN 0910-AJ16)" (one_shot, March 2027) - "Australia H5N1 transmission to poultry or local wildlife" (ongoing) - "Definium DT120 Phase 3 GAD and low-dose MDD trial readouts" (one_shot, late 2026) - "FDA finalization and launch of Expedited-IND Pilot Program" (one_shot, Sept 30, 2026) - "Sobi BLA resubmission for NASP in uncontrolled gout" - "Achieve Life Sciences NDA resubmission for cytisinicline in smoking cessation" (one_shot, Q4 2026) - "EMA re-examination outcome on Omeros's narsoplimab in TA-TMA" - "GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP" (one_shot, Q3 2026) - "Merck regulatory filing for tulisokibart in ulcerative colitis" (one_shot, Q1 2027) - "MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa" (one_shot, late Sept 2026) - "FDA regulatory decision on Exelixis' zanzalintinib plus Tecentriq in late-line mCRC" (one_shot, Dec 3, 2026) - "FDA traditional approval decision on Novartis's Vanrafia (atrasentan) in IgAN" (one_shot, late 2026) - "Dianthus MoMeNtum Phase 2 top-line data in MMN" (one_shot, Q4 2026) - "Dianthus CAPTIVATE Part B top-line guidance in CIDP" (one_shot, late 2026) - "FDA regulatory decision on Gilead's once-weekly oral Yeztugo for HIV PrEP" (one_shot, Feb 2, 2027) - "FDA regulatory decision on Zepzelca's second-line SCLC indication" - "USDA $750M sterile screwworm fly facility operational launch in Texas" (one_shot, late 2027) - "Sanofi Tzield Phase 3 BETA-PRESERVE confirmatory trial in Stage 3 T1D" (one_shot, late 2028) - "FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination" (one_shot, June 2027) - "FDA regulatory filing and decision on Takeda's zasocitinib in plaque psoriasis" (one_shot, April 2027) - "FDA regulatory filing and decision on Eli Lilly's Foundayo in Type 2 diabetes" (one_shot, April 2027) - "Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP" (one_shot, June 2027) - "Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP" (one_shot, June 2027) - "Eli Lilly SURPASS T1D-1 Phase 3 trial readout in Type 1 Diabetes" (one_shot, Nov 2026) - "DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout" (one_shot, June 2027) - "Alterity Therapeutics ATH434 Phase 3 MSA trial initiation" (one_shot, late 2026) - "Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision" (one_shot, mid-2027) - "Pfizer berobenatide Phase 3 obesity trial readout" (one_shot, late 2027) - "Phase 3 trial readout for VGA039 in von Willebrand disease" (one_shot, late 2028) - "ISS Russian Zvezda module air leaks and repairs" (ongoing) - "FDA regulatory decision on giredestrant in HR+ early-stage breast cancer" (one_shot, Nov 2026) - "FDA regulatory decision on bezuclastinib in GIST" (one_shot, Nov 2026) - "Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout" (one_shot, no date) - "sBLA submission for Zynlonta plus rituximab in r/r DLBCL" (one_shot, Q4 2026) - "NHS-Galleri trial cancer mortality data release" (ongoing) - "NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC)" (one_shot, Feb 2027) - "Global Phase 3 trial readouts for ivonescimab (HARMONi studies)" (ongoing) - "Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines" (ongoing) Let's do some search for Scholar Rock, MoonLake, GondolaBio, etc., which are targeted for Q3 2026 or late September 2026, to see if there are any updates. Let's also look for updates on the FDA's Expedited-IND Pilot Program and Operation Trailblazer, since the comment period closed in July 2026. Let's search for "Expedited-IND Pilot Program" or "Operation Trailblazer" "FDA" "Qualified Research Institutions". First, let's search for the big approvals we just saw: - Genglycos (pariglasgene brecaparvovec) by Ultragenyx - mFLUSIVA (Moderna seasonal flu mRNA vaccine) - Mimrylo (rusfertide) - Zenbexus (iberdomide) - Tudriqev (vusolimogene oderparepvec) Let's do a search on `mFLUSIVA` and `Genglycos` to gather the primary press releases and details.

This is a critical milestone: **mFLUSIVA** (mRNA-1010) was approved by the FDA on August 5, 2026, as the first mRNA-based influenza vaccine for adults 50 years and older. This is a massive development in public health and vaccine technology. Let's check the other approvals as well: - **Tudriqev (vusolimogene oderparepvec)** (formerly RP1) by Replimune was approved on August 6, 2026. This is an oncolytic immunotherapy for melanoma. - **Genglycos (pariglasgene brecaparvovec-opnr)** (formerly DTX401) by Ultragenyx was approved on August 19, 2026. - **Mimrylo (rusfertide)** by Takeda was approved on August 28, 2026. - **Zenbexus (iberdomide)** by Bristol Myers Squibb was approved on August 13, 2026. Let's search for details on the approvals of Tudriqev, Genglycos, Mimrylo, and Zenbexus to get high-quality details, links, and quotes. Let's do a search on Tudriqev first.

Excellent. Now we have high-quality details on Replimune's Tudriqev approval. Let's look for details on Ultragenyx's gene therapy approval: **Genglycos (pariglasgene brecaparvovec-opnr)** (formerly DTX401) on August 19, 2026. Let's do a search on `Genglycos`.

Perfect! We have two major gene/immunotherapy approvals to report with excellent detail: 1. **mFLUSIVA** (mRNA-1010) - first mRNA influenza vaccine, approved August 5, 2026. 2. **Tudriqev** (vusolimogene oderparepvec-wtpg) - oncolytic viral therapy for advanced cutaneous melanoma, approved August 6, 2026, after two previous CRLs. 3. **Genglycos** (pariglasgene brecaparvovec-opnr) - first gene therapy for Glycogen Storage Disease Type Ia (GSDIa), approved August 19, 2026. Let's check on other open watches to see if they have fired. - "FDA regulatory decision on Scholar Rock's apitegromab BLA in SMA" (one_shot, target Sept 30, 2026). Let's search if there has been an approval or update for apitegromab. - "FDA public hearing on therapeutic use of psychedelic drugs" (one_shot, scheduled for Sept 14, 2026). This is in the future (today is Sept 3, 2026). - "FDA Advisory Committee meeting on GRAIL's Galleri MCED test" (one_shot, scheduled for Sept 23, 2026). This is in the future. - "Definium Phase 3 Panorama trial readout of DT120 in GAD" (one_shot, expected Sept 2026). Let's search for "Definium Panorama" or "DT120" or "Definium Therapeutics". - "MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa" (one_shot, targeted for late September 2026). Let's check if it has been submitted. - "GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP" (one_shot, targeted for Q3 2026). Let's check this. - "Australia H5N1 transmission to poultry or local wildlife" / "New Zealand H5N1 transmission to poultry or wildlife sanctuaries". Let's search for bird flu (H5N1) updates in Australia and New Zealand. - Let's search for "Operation Trailblazer" or "Expedited-IND Pilot Program" updates. Let's do a search on Scholar Rock's apitegromab first.

This is a very important update for Scholar Rock's apitegromab BLA in SMA! Let's examine: - On August 7, 2026, Scholar Rock announced that the FDA review of the apitegromab BLA is progressing with the Company's second fill-finish facility, and the PDUFA date is September 30, 2026. - The company removed the Catalent Indiana LLC facility from the BLA because the FDA classified the April 2026 site inspection of Catalent Indiana as Official Action Indicated (OAI). This facility was previously the source of the CRL in September 2025. - By utilizing the second fill-finish facility, the BLA remains on track for potential approval by September 30, 2026. This represents a direct update to the watch: "FDA regulatory decision on Scholar Rock's apitegromab BLA in SMA" (`01a030ca-8bbc-74d9-aad8-2f305e2757e3`). The PDUFA date is September 30, 2026, which is in this month. So the watch is not yet fired (it fires when the FDA grants approval or CRL on or before Sept 30, 2026), but the *update* on the fill-finish site and the OAI status of Catalent Indiana is a major story. We can write a note about this. Wait, let's search for "Definium Panorama" or "DT120" to see if there are any updates on Definium's Phase 3 Panorama trial readout of DT120 in GAD, expected in September 2026. Let's do a search.

Ah, the Voyage study results were released in August 2026! But the Panorama study (the one we are watching for) is still expected to read out in September 2026. Wait, let's look at the watch: "Definium Phase 3 Panorama trial readout of DT120 in GAD" (`01a0079b-2493-7ec5-b616-680631330a60`). The trigger is "Fires when Definium reports topline Phase 3 Panorama trial data for DT120 in GAD." The fire date is September 30, 2026. It has not fired yet, but Voyage (the other Phase 3 trial) read out on August 2026 with positive results. Wait, let's check if Panorama has read out very recently (remember today is Sept 3, 2026). Let's do a search on "Definium Panorama" to see if there is any announcement in the last week.

Okay, Panorama is scheduled for around September 23 to 30, 2026. This means it hasn't read out yet, but the Voyage data in August was a massive precursor. Let's check other watches. What about "FDA public hearing on therapeutic use of psychedelic drugs" (`01a04564-e836-7517-8d40-771bcd125f8f`) scheduled for September 14, 2026? It's in the future. What about "FDA Advisory Committee meeting on GRAIL's Galleri MCED test" (`01a0079b-680b-7359-8e07-478358915d9c`) scheduled for September 23, 2026? It's in the future. What about "MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa" (`019ef183-efef-70f6-9f55-cbbd11c943bb`) targeted for late September 2026? Let's check if there is any update on Sonelokimab or MoonLake. Let's do a search.

So MoonLake plans to submit its BLA for hidradenitis suppurativa by the end of September 2026. This confirms our watch is on track but has not fired yet. Let's check "GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP" (`019ef6aa-0088-716a-a75d-6adbc6f4984d`) targeted for Q3 2026. Let's search for "GondolaBio" or "PORT-77" or "PATHWAY".

Let's search for "GondolaBio PATHWAY trial PORT-77" on Google to see if there is any press release or clinicaltrials.gov entry showing the trial has been initiated or registered. Let's do a search.

Ah, the search budget is spent. No more searches. I must now write up the findings I have and resolve any threads or watches based on the evidence I've collected, and then call finish_cycle. Wait, let's review what we found. We have three major new drug approvals: 1. **Moderna's mFLUSIVA** (mRNA-1010) seasonal influenza vaccine was approved by the FDA on August 5, 2026, for adults 50 years and older. This is the first-ever mRNA seasonal influenza vaccine approved by the FDA. 2. **Replimune's Tudriqev** (vusolimogene oderparepvec-wtpg) in combination with nivolumab (Opdivo) was granted accelerated approval by the FDA on August 6, 2026, for adult patients with unresectable advanced cutaneous melanoma that progressed on a PD-1-blocking antibody-based regimen. This is a massive milestone, as it's the first oncolytic virus therapy approved since 2015, and it succeeded on its third try (overcoming two previous CRLs). 3. **Ultragenyx's Genglycos** (pariglasgene brecaparvovec-opnr) gene therapy (formerly DTX401) was granted accelerated approval on August 19, 2026, for glycogen storage disease type Ia (GSDIa) in patients 8 years and older. This is the first-ever FDA-approved treatment targeting the underlying genetic cause of GSDIa. Let's check if any of these match the watches we listed: - Watch `019feddb-a316-76c7-beeb-a199a4b65d4b` is: "Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev in melanoma". It says: "Monitor the Phase 3 IGNYTE-3 randomized confirmatory trial results for Replimune's Tudriqev in advanced melanoma (expected by late 2027), which is required to support its accelerated approval." Wait, the accelerated approval *itself* happened now. The watch is for the Phase 3 IGNYTE-3 confirmatory trial results (expected by late 2027) which is required to support the accelerated approval. So the watch is ongoing/not fired yet (or rather, it's a one-shot watch expected in late 2027, so it hasn't fired yet). But we can definitely write a note about Tudriqev's accelerated approval! Wait, let's look at the other watches. Wait! Is there an open thread or watch for the approval of DTX401 (Genglycos) or mRNA-1010 (mFLUSIVA)? Let's check the threads again. Ah, we have: - "Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout" (one_shot, no date) - this is for the bird flu vaccine (mRNA-1018), not seasonal flu (mRNA-1010). - Wait, do we have any watches that have fired? Let's check the list of threads for anything that has fired. Wait, let's look at: - "Scholar Rock's apitegromab BLA in SMA" (`01a030ca-8bbc-74d9-aad8-2f305e2757e3`). The description is: "Monitor the FDA's regulatory decision on Scholar Rock's apitegromab BLA for spinal muscular SMA following the removal of the Catalent Indiana facility." The fire date is September 30, 2026. The trigger is "Scholar Rock". The decision is expected by Sept 30, 2026, and the company just announced on August 7, 2026, that the review is progressing with the second fill-finish facility and remains on track for potential approval by September 30, 2026. This is a major update, but the decision itself hasn't happened yet, so the watch doesn't resolve yet. - Let's look at other watches. None of them seem to have fully fired. Wait, let's check if we have any other open threads or findings to update. Let's check the list of relevant prior findings: - `hhs-clinical-trials-reform-operation-trailblazer` - `fda-commissioners-national-priority-voucher-program` - `fda-crl-public-disclosure-policy` - `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance` None of these are direct matches for the three approvals we found (mFLUSIVA, Tudriqev, Genglycos). Wait, are there any other prior findings? Let's check using `read_notes` to see if we have notes on Replimune (Tudriqev / RP1) or Ultragenyx (DTX401 / Genglycos) or Moderna's influenza vaccine (mRNA-1010). Let's call `read_notes` to be absolutely sure we don't duplicate a slug! This is a critical rule: "Before you write, scan your prior findings (the injected block + `read_notes`) for the slug that already owns this subject and reuse it". Let's do that.

Perfect! We have a complete mapping of existing slugs. Let's review the notes we already have: - `replimune-rp1-melanoma-fda-review` (Title: "FDA Advisory Committee Backs Replimune's Twice-Rejected RP1 in Advanced Melanoma") -> We should update this slug (`replimune-rp1-melanoma-fda-review` or we can update `replimune-rp1-melanoma-fda-review` to cover the accelerated approval on August 6, 2026! Wait, actually, let's see if there is another slug. No, `replimune-rp1-melanoma-fda-review` is exactly the slug for Replimune's RP1 in advanced melanoma). - `genglycos-gsdia-gene-therapy-fda-approval` (Title: "FDA Grants Accelerated Approval to Ultragenyx's Genglycos, the First-Ever Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)") -> Wait, this note already exists! Yes, it was created on Sep 3, 2026. - `definium-dt120-lysergide-anxiety-phase-3` (Title: "Definium's DT120 Orally Disintegrating Tablet (Lysergide) Achieves Landmark Phase 3 Success in Generalized Anxiety Disorder") -> This note already exists and was updated on Sep 2, 2026. - `scholar-rock-apitegromab-sma-manufacturing-update` (Title: "Scholar Rock Drops Catalent Indiana to De-Risk FDA Review of Spinal Muscular Atrophy Candidate Apitegromab") -> This note already exists. - `uniqure-amt130-huntington-disease-bla-submission` (Title: "uniQure Submits Historic BLA for Huntington's Disease Gene Therapy AMT-130") -> This note already exists. It was updated on Sep 2, 2026. This means the Huntington's BLA has been submitted! Let's check if this resolves the watch `01a0644a-2b51-7823-bbb3-eba810d99fe4`. Wait! The watch is: "FDA regulatory decision on uniQure's AMT-130 BLA in Huntington's disease" (one_shot, trigger: "Fires when the FDA grants accelerated approval or issues a Complete Response Letter (CRL) for AMT-130 in Huntington's disease."). The BLA was just *submitted* on September 2, 2026. The FDA decision (approval or CRL) has not happened yet, so the watch is still open. Wait, let's look at the watch for "Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev in melanoma" (`019feddb-a316-76c7-beeb-a199a4b65d4b`). The accelerated approval has occurred. Let's write a note updating `replimune-rp1-melanoma-fda-review` to document the accelerated approval of Tudriqev (RP1) on August 6, 2026! Wait, let's look at the other major approval: **mFLUSIVA** (mRNA-1010) seasonal influenza vaccine by Moderna, approved August 5, 2026. Is there a slug for this? Let's check the list of notes. No, there is no slug for `mflusiva` or `moderna-mrna-seasonal-influenza-vaccine`. This is a brand new, major story! We should mint a fresh slug for this: `moderna-mflusiva-mrna-influenza-vaccine-fda-approval`. Let's do that. Let's double check if we have any other updates. Wait, let's look at `scholar-rock-apitegromab-sma-manufacturing-update` (`scholar-rock-apitegromab-sma-manufacturing-update`). It already has a title: "Scholar Rock Drops Catalent Indiana to De-Risk FDA Review of Spinal Muscular Atrophy Candidate Apitegromab". Let's check if we need to update it. The announcement on August 7, 2026, about the FDA review progressing with the second fill-finish facility and removing Catalent Indiana is already covered by this note (as the title says "Scholar Rock Drops Catalent Indiana"). So we don't need to write a new note for that unless there's a further update (which we didn't find, as the PDUFA date is Sept 30, 2026). Let's check `replimune-rp1-melanoma-fda-review`. Let's write the update for it to document the accelerated approval on August 6, 2026. Wait, let's read the current content of `replimune-rp1-melanoma-fda-review` if we can. Actually, we can just write the updated version of `replimune-rp1-melanoma-fda-review` using `write_note`. Let's structure the update beautifully. Let's check if there are other watches or threads we can resolve. Wait, is there any thread or watch that has fired? Ah! Let's check if any watch has fired. Wait, let's look at: "Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev in melanoma" (`019feddb-a316-76c7-beeb-a199a4b65d4b`). Wait, the trigger is "Fires when Replimune reports topline Phase 3 IGNYTE-3 confirmatory trial data for Tudriqev + nivolumab in advanced melanoma." The fire date is December 31, 2027. This hasn't happened yet. What about "Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout" (`019e9f1e-f092-7114-960b-1c3b5c994320`)? This is for the bird flu vaccine, not the seasonal flu vaccine (mFLUSIVA / mRNA-1010). So it hasn't fired yet. Wait, are there any other watches? Let's check: "FDA regulatory decision on Scholar Rock's apitegromab BLA in SMA" (`01a030ca-8bbc-74d9-aad8-2f305e2757e3`). The fire date is September 30, 2026. It hasn't fired yet because the decision hasn't been made. Let's write the note for **mFLUSIVA**: Slug: `moderna-mflusiva-mrna-influenza-vaccine-fda-approval` Title: FDA Approves Moderna's mFLUSIVA, the World's First mRNA Seasonal Influenza Vaccine Let's write the note for **Tudriqev**: Slug: `replimune-rp1-melanoma-fda-review` Title: FDA Grants Accelerated Approval to Replimune's Tudriqev, Overcoming Two Previous CRLs in Advanced Melanoma Let's carefully verify the guidelines for writing notes: - Body shape: # <Title> <what's happening, told through the specifics — the real quote(s) and the real link(s)> ## Sources - [Story / article title](https://url) — one-line gloss - [Comment by user](https://news.ycombinator.com/item?id=...) — one-line gloss - No YAML frontmatter. - Use stable slugs. Let's write these two notes now. First, the note for `moderna-mflusiva-mrna-influenza-vaccine-fda-approval`.

Now I will write the updated note for `replimune-rp1-melanoma-fda-review`. I will reuse the slug to update the existing note in place, bringing the story forward to show that the drug has now received accelerated approval from the FDA. Let's write it.

This is excellent! I have successfully documented these two major stories. Let's check if there are any other notes or threads we can resolve. Wait, let's look at the threads we have. Is there an active thread for Replimune? Let's see: we don't have an open thread for Replimune's approval itself (we have a watch for the Phase 3 IGNYTE-3 trial results in late 2027). Wait, do we have any other open threads or watches that can be resolved or updated? Let's check: - "FDA regulatory decision on Scholar Rock's apitegromab BLA in SMA" (`01a030ca-8bbc-74d9-aad8-2f305e2757e3`). The PDUFA date is September 30, 2026. The decision hasn't been made yet, so we cannot resolve this watch. - "Definium Phase 3 Panorama trial readout of DT120 in GAD" (`01a0079b-2493-7ec5-b616-680631330a60`). The readout is expected in September 2026. It hasn't read out yet, so we cannot resolve this watch. Since there are no other watches that have fired or threads to resolve, I will call `finish_cycle` to complete this cycle. Let's do that.

I have successfully completed the research cycle. Here is a summary of the findings and updates from this cycle: ### 1. **Moderna's mFLUSIVA Approved as World's First mRNA Seasonal Flu Vaccine** * **What's New:** On August 5, 2026, the FDA approved Moderna's **mFLUSIVA (mRNA-1010)** for seasonal influenza in adults aged 50 and older. * **Significance:** This is a major technical milestone, marking the first approved mRNA seasonal flu vaccine. It represents a significant expansion of the mRNA platform beyond COVID-19 and RSV. * **Details:** The approval was supported by a unanimous recommendation from the FDA’s VRBPAC in June 2026 and clinical data from a Phase 3 trial involving over 40,000 participants. This approval successfully resolved a rare Refusal-to-File (RTF) letter issued by the FDA in February 2026. * **Living Note Updated:** Coined a new durable subject note under the slug `moderna-mflusiva-mrna-influenza-vaccine-fda-approval`. ### 2. **Replimune's Tudriqev Wins Accelerated FDA Approval in Advanced Melanoma** * **What's New:** On August 6, 2026, the FDA granted accelerated approval to Replimune Group's **Tudriqev (vusolimogene oderparepvec-wtpg)** in combination with nivolumab (Opdivo) for adult patients with unresectable advanced cutaneous melanoma progressing on prior anti-PD-1 therapy. * **Significance:** This is the first FDA approval of an engineered oncolytic virus therapy since Amgen's T-VEC in 2015. * **Details:** The approval marks a major regulatory turnaround, as Replimune overcame two prior Complete Response Letters (CRLs) in July 2025 and April 2026, culminating in a 10-to-3 positive vote from the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) on July 30, 2026. The approval is based on a 24.2% objective response rate (ORR) with a median duration of response (DOR) of 14.1 months in the IGNYTE trial. * **Living Note Updated:** Revised the existing note under the slug `replimune-rp1-melanoma-fda-review` to document this landmark approval. ### 3. **Other Key Pipeline Updates Checked:** * **Scholar Rock (Apitegromab in SMA):** On track for its September 30, 2026 PDUFA action date. The company successfully de-risked the review by removing the Catalent Indiana facility (which received an FDA OAI classification in April 2026) and progressing solely with its second fill-finish facility. * **Definium Therapeutics (DT120 in GAD):** Following its positive Phase 3 *Voyage* study results in August, the second pivotal Phase 3 study, *Panorama* (evaluating a low-dose 50 µg arm to address functional unblinding), remains on track for topline results in late September 2026.